Development of a method to detect very low levels of HER2 expression in Circulating Tumor Cells (CTCs) by liquid biopsy in patients with metastatic breast cancer

被引：0
|
作者：
Di Caro, Giuseppe
Bourdon, David
Kunihiro, Andrew
Cunsolo, Alessandra
Lam, Ernest
Slade, Megan
Blankfard, Martin
Schwartzberg, Lee
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO5-04-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO5-04-04
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
    Aktas, Bahriye
    Kasimir-Bauer, Sabine
    Mueller, Volkmar
    Janni, Wolfgang
    Fehm, Tanja
    Wallwiener, Diethelm
    Pantel, Klaus
    Tewes, Mitra
    BMC CANCER, 2016, 16
  • [32] Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
    Aktas, B.
    Kasimir-Bauer, S.
    Mueller, V.
    Rack, B.
    Janni, W.
    Pantel, K.
    Fehm, T.
    Tewes, M.
    CANCER RESEARCH, 2013, 73
  • [33] Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
    Bahriye Aktas
    Sabine Kasimir-Bauer
    Volkmar Müller
    Wolfgang Janni
    Tanja Fehm
    Diethelm Wallwiener
    Klaus Pantel
    Mitra Tewes
    BMC Cancer, 16
  • [34] Correlation of Expression of HER2 in Circulating Tumor Cells and in Corresponding Primary Tumors in Breast Cancer Patients
    Harigopal, M.
    Galullo, P.
    Levy, G.
    Hui, P.
    Kowalski, D.
    Rimm, D. L.
    Chhieng, D.
    MODERN PATHOLOGY, 2011, 24 : 92A - 92A
  • [35] Correlation of Expression of HER2 in Circulating Tumor Cells and in Corresponding Primary Tumors in Breast Cancer Patients
    Harigopal, M.
    Galullo, P.
    Levy, G.
    Hui, P.
    Kowalski, D.
    Rimm, D. L.
    Chhieng, D.
    LABORATORY INVESTIGATION, 2011, 91 : 92A - 92A
  • [36] The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
    Wallwiener, Markus
    Hartkopf, Andreas Daniel
    Riethdorf, Sabine
    Nees, Juliane
    Sprick, Martin Ronald
    Schoenfisch, Birgitt
    Taran, Florin-Andrei
    Heil, Joerg
    Sohn, Christof
    Pantel, Klaus
    Trumpp, Andreas
    Schneeweiss, Andreas
    BMC CANCER, 2015, 15
  • [37] The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
    Markus Wallwiener
    Andreas Daniel Hartkopf
    Sabine Riethdorf
    Juliane Nees
    Martin Ronald Sprick
    Birgitt Schönfisch
    Florin-Andrei Taran
    Jörg Heil
    Christof Sohn
    Klaus Pantel
    Andreas Trumpp
    Andreas Schneeweiss
    BMC Cancer, 15
  • [38] Acquisition of HER2/neu over-expression on circulating tumor cells (CTCs) in patients (pts) with advanced breast cancer (ABC) during chemotherapy
    Munzone, E.
    Nole, F.
    Zorzino, L.
    Medici, M.
    Minchella, I.
    Cassatella, M. C.
    Casadio, C.
    Picozzi, M.
    Adamoli, L.
    Goldhirsch, A.
    Sandri, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] ACQUISITION OF HER2/NEU OVER-EXPRESSION ON CIRCULATING TUMOR CELLS (CTCS) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (ABC) DURING CHEMOTHERAPY
    Nole, F.
    Munzone, E.
    Zorzino, L.
    Cassatella, C.
    Casadio, M. C.
    Verri, E.
    Cossu-Rocca, M.
    Aurilio, G.
    Sciandivasci, A.
    Picozzi, M.
    Adamoli, L.
    Botteri, E.
    Rotmensz, N.
    Goldhirsch, A.
    Sandri, M.
    ANNALS OF ONCOLOGY, 2009, 20
  • [40] The HER2 circulating ratio to define HER2 expressing circulating tumor cells in advanced breast cancer
    D'Amico, Paolo
    Gerratana, Lorenzo
    Shah, Ami
    Zhang, Qiang
    Davis, Andrew
    Zhang, Youbin
    Jacob, Saya
    Vagia, Elena
    Behdad, Amir
    Reduzzi, Carolina
    Curigliano, Giuseppe
    Cristofanilli, Massimo
    CANCER RESEARCH, 2021, 81 (04)
12345